RE:RE:RE:Sanofi Exploring Acquisition of KRAS Cancer Drugmaker MiratiIn a Monday note to clients, William Blair analyst Matt Phipps, Ph.D. said BMS valued the deal largely based on the potential of Krazati.
In December 2022 Krazati won an FDA accelerated approval for previously treated KRAS G12C-mutant NSCLC.
https://www.fiercepharma.com/pharma/bristol-myers-buys-mirati-58b-i-o-giant-branches-out-targeted-therapy-cancer